Drugs / autologous chondrocytes
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05553132 | Aug 2023 → Dec 2026 expected | cartilage development disorder | Daniel B. F. Saris | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03137914 | May 2015 → May 2016 | temporomandibular joint disorder | Faculdade de Medicina de Petrópolis Faculdade Arthur Sá Earp Neto | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02770209 | Feb 2012 → Aug 2013 | articular cartilage disorder | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Chondrocytes | “intraarticular injection into the TMJ (arthrocentesis) of autologous chondrocytes diluted in hyaluronic acid” NCT03137914 ↗ |
| Known as | Chondrons | “Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier” NCT05553132 ↗ |
| Action | Restore | “Cartilage cells are being used from the rim of the defect in the hip and recycled to help make new cartilage in the hip.” NCT05553132 ↗ |
| Modality | Cell therapy | “This study is aimed at evaluating the feasibility and effectiveness of a completely natural tissue engineered cartilage, composed of a self-made tissue engineered oriented...” NCT02770209 ↗ |
| Route | Other | “intraarticular injection into the TMJ (arthrocentesis) of autologous chondrocytes diluted in hyaluronic acid” NCT03137914 ↗ |